Alluvi, previously BI 4744, offers a significant development in obesity therapy. This dual activator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/